Di Wu, B.Pharm., Ph.D., FCP
Postdoctoral Fellow, The Ohio State University, Clinical and Preclinical Pharmacology
Di Wu, B.Pharm., Ph.D., FCP, is the Director of the Laboratory for International Research within The Children’s Hospital of Philadelphia’s Division of Clinical Pharmacology & Therapeutics and is a Guest Professor at Central South University & Third Xiangya Hospital. Dr. Wu additionally serves as a Clinical Investigator, and designs clinical trials, experiments, and approaches for data analysis at the Kinetic Modeling and Simulation Core, which serves both The Children’s Hospital of Philadelphia and the University of Pennsylvania. She also consults for hospitals and pharmaceutical companies on issues related to pharmacy practice, intellectual property, market analysis, and development strategy.
Dr. Wu’s career is focused on conducting clinical trials and research in China and the United States in order to develop clinical best practices for pharmacotherapies. She investigates both exploratory compounds and traditional medicines which fight diseases in adult and pediatric populations. Her research examines the mechanism of action of drugs, identifies and validates disease biomarkers, and investigates the impact of human developmental changes on drug disposition. To do this, Dr. Wu utilizes a variety of methodologies, including modeling & simulation (e.g. pharmacokinetics/pharmacodynamics), systems biology, pharmacognosy, and bioanalytical approaches. Dr. Wu has published over 50 peer-reviewed papers, book chapters, and conference abstracts. She serves as a reviewer for seven internationally-circulated journals, and is an editorial board member for two scientific journals.
Key Publications and Research:
Textbook chapter on pediatric clinical trials used by graduate students in medical/pharmaceutical schools across China:
Textbook chapter on integrated systems biology and translational medicine research
Peer-reviewed journal pubications on methodologies:
Wu D, Wade KC, Paul DJ, Barrett JS. A rapid and sensitive LC-MS/MS method for determination of fluconazole in human plasma and its application in infants with Candida infections. Therapeutic Drug Monitoring, 2009, 31(6): 703-709.
Byrd JC, Lin TS, Dalton JT, Wu D, Phelps MA, Fischer B, Moran M, Blum KA, Rovin B, Brooker-McEldowney M, Broering S, Schaaf LJ, Johnson AJ, Lucas DM, Heerema NA, Lozanski G, Young DC, Suerez JR, Colevas AD, Grever MR. Flavopiridol administered using a pha an rmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia. Blood, 2007, 109(2): 399-404.